Press Release
Press Release
Press Contacts: Erik Cummins, Matt Hyams, Olivia Thomas
12.16.21
A Pillsbury team led by partner Stan Lewandowski and senior associate Mediha Ali in Silicon Valley represented the co-lead investor McWin in the closing of $175 million in Series C financing for the EVERY Company, the leading precision fermentation platform accelerating a global transition to animal-free protein.
The round was co-led by new investor, McWin, and existing investor, Rage Capital. Other new and existing investors joined the round including Temasek, Grosvenor’s Wheatsheaf Group, and TO Ventures. Prosus Ventures also contributed to the funding, marking its first investment in synthetic biology.
Notably, the Series C round raised by EVERY (formerly Clara Foods) was heavily oversubscribed due to strong investor appetite to fill the growing supply gap for animal-free protein and ingredient solutions. The Series C round brings EVERY’s total funding to $233 million. EVERY will use the capital to scale production, commercialize a robust pipeline of animal-free protein products nationwide, and expand into a broad array of new food applications. EVERY will also continue to expand its protein production platform by mining the egg proteome for novel, hyper-functional proteins.